Related Experiment Videos
Chronic myeloid disorders: Classification and treatment overview
1Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
Seminars in Hematology
|March 10, 2001
Summary
Chronic myeloid disorders (CMD) involve abnormal white blood cell proliferation. Classification relies on morphology and cytogenetics, aiding clinical management of these myeloproliferative diseases.
Area of Science:
- Hematology
- Oncology
Background:
- Chronic myeloid disorders (CMD) are characterized by monoclonal myeloproliferation across multiple cell lineages.
- Monoclonal hematopoiesis is not exclusive to CMD, necessitating precise diagnostic criteria.
- Morphologic and cytogenetic features are crucial for a clinically useful classification of CMD.
Purpose of the Study:
- To outline a working classification of chronic myeloid disorders.
- To differentiate major CMD categories including CML, MDS, CMPD, and atypical CMD.
- To define diagnostic criteria for specific CMPD subtypes like polycythemia vera and essential thrombocythemia.
Main Methods:
- Review of morphologic and cytogenetic characteristics of CMD.
- Differentiation of four major CMD divisions: CML, MDS, CMPD, and atypical CMD.
- Establishment of diagnostic criteria for polycythemia vera, essential thrombocythemia, and agnogenic myeloid metaplasia.
Main Results:
- Four major CMD divisions identified: CML, MDS, CMPD, and atypical CMD.
- CML is identified by the Philadelphia chromosome.
- CMPD subtypes require exclusion of reactive causes and specific clinical/laboratory findings.
Conclusions:
- A structured classification of CMD based on morphology and cytogenetics is clinically valuable.
- Accurate diagnosis of CMD subtypes, particularly CMPD, relies on excluding reactive conditions and meeting specific criteria.
- This classification aids in understanding and managing diverse chronic myeloid disorders.